Sandoz Puts Aflibercept In Its Sights With Phase III Data
Biosimilar Player Says It Will Offer ‘Differentiating Feature’ For Eylea Rival
Sandoz is looking to move ahead with its planned filings for one of the most significant off-patent biologic opportunities in the coming years – Eylea (aflibercept).
